Prescription Medicines
Daimit XR Tab.
- Product Category
- Diabetes treatment
- Active Ingredients
- metformin hydrochloride
- Appearance
- A white, biconvex, oblong, extended-release tablet.
- Reimbursement Code
- 648100320
01 / 02
1. Composition and Strength
1 tablet
- Active ingredient: Metformin hydrochloride (BP)----500mg
- Additives: Magnesium stearate, carbomer, hydroxypropyl cellulose, hypromellose 2208
2. Effectiveness
Treatment of adult patients with type 2 diabetes who have insufficient blood sugar control through diet and exercise therapy. (Especially in overweight diabetic patients)
- This drug can be used as monotherapy or in combination with other oral hypoglycemic agents or insulin.
3. Dosage and dosage
The administered dose should be determined for each individual based on drug effectiveness and tolerability, and should not exceed the recommended maximum daily dose.
- The typical initial dose is 500 mg metformin hydrochloride extended-release tablet once a day with dinner.
- The dosage should be adjusted by measuring blood sugar levels after a week. Gastrointestinal adverse reactions can be improved with gradual dose increase. The maximum dose is 2000 mg per day.
- When increasing the dose, increase by 500 mg per week, and up to 2000 mg per day can be administered with dinner. If blood sugar control is not achieved even with up to 2,000 mg once a day, consider administering 1,000 mg twice a day, both times with meals.
- In patients already being treated with metformin tablets, the initial dose of this agent is the same as the daily dose of short-acting metformin tablets. For patients taking more than 2000 mg of short-acting metformin tablets per day, switching to this medication is not recommended.
- When starting medication and adjusting the dose, fasting blood sugar should be measured to measure the therapeutic response to this drug and confirm the minimum effective dose. The concentration of glycated hemoglobin in the blood should be measured at approximately 3-month intervals.
- The treatment goal of this drug is to reduce fasting blood sugar and blood glycated hemoglobin concentration to normal or close to normal levels by administering it at the minimum effective dose when administered as monotherapy or in combination with sulfonylureas or insulin.
patients with renal impairment
This drug can be used in patients with stage 3a moderate renal impairment (creatinine clearance [CrCl] 45≤~<60ml/min or glomerular filtration rate (GFR) 45≤~<60 mL/min/1.73 m2) if they are not accompanied by other symptoms that may increase the risk of lactic acidosis by adjusting the dose as follows.
- The starting dose is 500mg or 750mg once a day. The maximum daily dose is 1000 mg.
Renal function should be closely monitored every 3 to 6 months.
If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, administration of this drug should be discontinued immediately.
4. Precautions for use
1. Warning
1) In rare cases, severe lactic acidosis may occur. Cases of death due to lactic acidosis have been reported.
2) When administered concurrently with other antidiabetic agents such as insulin or sulfonylurea, caution is required as severe hypoglycemia may occur in rare cases.
2. Do not administer to the following patients
1) Patients with moderate (stage3b) and severe renal impairment (creatinine clearance <45ml/min or glomerular filtration rate <45ml/min/1.73m2), acute conditions that may affect renal function such as dehydration, serious infection, cardiovascular collapse (shock), acute myocardial infarction, and sepsis.
2) Patients with acute and unstable heart failure
3) Patients receiving tests that involve intravenous administration of radioiodine contrast material (e.g. intravenous urography, intravenous cholangiography, angiography, computed tomography using contrast media, etc.) (can cause acute renal failure, and are associated with lactic acidosis in patients receiving this drug. Therefore, among patients scheduled for such tests, if the glomerular filtration rate is >60ml/min/1.73m2, at least at the time of the test or in advance The drug must be discontinued, and re-administration is not possible within 48 hours. In patients with moderate renal impairment (glomerular filtration rate 45 to 60 ml/min/1.73 m2), re-administration is not possible within 48 hours after renal function is re-evaluated. Treatment is resumed only after this.)
4) Patients with a history of hypersensitivity to the ingredients of this drug or biguanide drugs
5) Patients with acute or chronic metabolic acidosis, including type 1 diabetes, lactic acidosis, diabetic ketoacidosis with or without coma, and patients with a history of ketoacidosis [Type 1 diabetes and diabetic ketoacidosis are treated with insulin.]
6) Diabetic precoma
7) In patients with severe infections or severe traumatic systemic disorders, treatment with this drug should be temporarily stopped and treatment should be restarted when the patient's oral intake is restored and renal function is found to be normal.
8) In the case of surgical procedures (excluding minor surgeries where there are no restrictions on food and fluid intake), this drug should be temporarily stopped 48 hours before surgery, and treatment should be restarted at least 48 hours after renal function is confirmed to be normal.
9) Patients with malnutrition, starvation, weakness, pituitary dysfunction, or adrenal dysfunction
10) Impaired liver function (since impaired liver function is associated with some cases of lactic acidosis, administration of this drug should generally be avoided in patients with clinical or laboratory evidence of liver disease), acute or chronic diseases that may cause tissue hypoxia such as respiratory failure, acute myocardial infarction, and shock, excessive alcohol intake, and patients with gastrointestinal disorders such as dehydration, diarrhea, and vomiting.
11) Pregnant women at risk of placental insufficiency, preeclampsia, and intrauterine growth retardation (see section 7. Administration for pregnant and lactating women)
3. Administer with caution to the following patients (there is a possibility of lactic acidosis and hypoglycemia).
1) Irregular meal intake, lack of meal intake
2) Intense muscle exercise
3) Patients taking interacting drugs
4. Adverse reactions
In post-marketing surveillance and clinical trial results, the side effects reported in patients receiving this drug were similar in nature and severity to the side effects reported in patients receiving metformin hydrochloride immediate-release tablets.
The following side effects may occur when taking this medicine:
Frequency is defined as follows: Very common: >1/10 Common: >1/100, <1/10 Uncommon: >1/1,000, <1/100 Rare: >1/10,000, <1/1,000 Very rare: <1/10,000
1) Metabolic and nutritional disorders
Common: vitamin B12 deficiency
Very rare: Lactic acidosis (lactic acidosis is rare but serious, and is a metabolic complication caused by accumulation of metformin hydrochloride during treatment. It is fatal in 50% of cases. Lactic acidosis occurs frequently in acute renal dysfunction, cardiopulmonary disease, and sepsis. Lactic acidosis may appear in conjunction with pathophysiological conditions, including diabetes, when there is significant tissue hypoperfusion and hypoxia. Lactic acidosis is characterized by increased blood lactic acid concentration (exceeding 5 mmol/L), decreased blood pH, electrolyte imbalance with increased difference between anions, and increased lactic acid/pyruvate ratio. When metformin hydrochloride is considered to be the cause of lactic acidosis, the blood concentration of metformin hydrochloride generally exceeds 5 μg/mL.
There are very few reports of the development of lactic acidosis in patients receiving metformin hydrochloride (approximately 0.03 cases per 1,000 patients per year, and approximately 0.015 fatal cases per 1,000 patients per year). The reported cases primarily occurred in diabetic patients with significantly reduced renal function, including intrinsic renal disease and renal hypoperfusion, in conditions such as multiple medical and surgical problems and combined administration of many drugs. The risk of lactic acidosis increases with the degree of renal function decline and the patient's age.
In addition, metformin hydrochloride should be discontinued immediately if symptoms related to hypoxia, dehydration, or sepsis appear. If liver function is impaired, the ability to excrete lactic acid may be significantly reduced, so metformin hydrochloride is generally not administered to patients with clinical or laboratory findings of liver disease. Since alcohol has the potential to affect metformin hydrochloride on lactic acid metabolism, acute or chronic excessive intake of alcohol should be avoided while receiving metformin hydrochloride.
The onset of lactic acidosis is sometimes difficult to distinguish and is accompanied by nonspecific symptoms such as malaise, myalgia, dyspnea, asthenia, and abdominal pain. If acidosis becomes more severe, a drop in body temperature, hypotension, and resistant bradyarrhythmia may occur. Patients and doctors should be aware of the importance of these symptoms, and patients should notify their doctors immediately if these symptoms occur. Serum electrolytes, ketones, blood sugar, blood pH (<7.35), lactic acid concentration, and blood metformin hydrochloride concentration may also be useful in confirming lactic acidosis. Additionally, if there is a high suspicion of lactic acidosis, necessary measures are taken without expecting a lactic acid measurement result. In particular, be careful because lactic acidosis is likely to occur when the initial dose is increased. Gastrointestinal symptoms often occur early in treatment once the patient has stabilized on a certain dose of metformin hydrochloride, but later gastrointestinal symptoms may be due to lactic acidosis or another serious illness.
Fasting venous plasma lactate concentrations above the upper limit of normal but below 5 mmol/L in patients receiving metformin hydrochloride do not indicate impending lactic acidosis and may be due to other mechanisms, such as poorly controlled diabetes or obesity, excessive physical activity, or technical problems in specimen handling. Lactic acidosis should be suspected in diabetic patients presenting with metabolic acidosis without evidence of ketoacidosis (ketonuria and ketonemia).
Lactic acidosis is a medical emergency requiring hospitalization. If lactic acidosis occurs in a patient receiving metformin hydrochloride, the drug should be discontinued immediately and general supportive therapy should be immediately administered. Since metformin hydrochloride is dialyzable (clearance up to 170 mL/min in good hemodynamic conditions), immediate hemodialysis is recommended to normalize acidosis and remove accumulated drug. This treatment sometimes results in immediate symptom improvement and recovery.
2) nervous system disorders
Common: taste impairment
3) Gastrointestinal disorders
Very common: Gastrointestinal disorders such as nausea, vomiting, diarrhea, abdominal pain, and anorexia.
These side effects occur most frequently in the early stages of treatment and disappear spontaneously in most cases. Gradually increasing the dose may help increase gastrointestinal tolerability. Since gastrointestinal symptoms occur in a dose-related manner during the initial stage of treatment, they can be reduced by gradually increasing the dose or administering metformin hydrochloride with meals. Severe diarrhea and/or vomiting may cause dehydration and prerenal azotemia and should be temporarily discontinued under these conditions. In patients stabilized on metformin hydrochloride, non-specific gastrointestinal symptoms may not be due to treatment but may be due to concurrent disease or lactic acidosis.
4) Skin and subcutaneous tissue disorders
Very rarely: erythema, itching, urticaria, rash, etc. may occur. In such cases, discontinue administration.
5. General precautions
1) Monitoring of renal function: This drug is mostly excreted by the kidneys, and the risk of accumulation of this drug and lactic acidosis increases depending on the degree of renal function impairment. Glomerular filtration rate should be evaluated before starting treatment and periodically thereafter. Patients with normal renal function should have a renal function test checked at least once a year. Patients with a creatinine clearance lower than normal and the elderly should have a renal function test performed at least 2 to 4 times a year. If the creatinine clearance rate is <45ml/min (glomerular filtration rate <45ml/min/1.73m2), discontinue treatment with this drug.
Special caution is needed in situations that may result in rapid renal function impairment, such as when there are symptoms of dehydration (severe or persistent vomiting or diarrhea) or when starting medications that affect renal function (such as antihypertensive drugs or diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs)). In these acute situations, metformin should be discontinued immediately and temporarily.
2) Diabetes-like symptoms: Consider application only to patients with an established diagnosis of diabetes. Be aware that in addition to diabetes, there are diseases with diabetes-like symptoms such as abnormal glucose tolerance and positive urine glucose (nephrogenic diabetes, geriatric glucose metabolism abnormalities, thyroid dysfunction, etc.).
3) Adjustment during administration: In cases where administration is no longer necessary, when a reduction is necessary, or when the effect becomes ineffective or insufficient due to the patient's deterioration, complications of infection, etc., pay attention to meal intake, weight change, blood sugar level, presence or absence of infection, etc., and pay attention to whether to continue administration, dosage, selection of drug, etc.
4) Hypoxic state: Cardiovascular collapse (shock) of any cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxia are associated with lactic acidosis and may cause prerenal azotemia. If this occurs in a patient receiving treatment with this drug, administration of this drug should be discontinued immediately.
5) Cardiac function: Patients with heart failure have a higher risk of hypoxia and decreased renal function. For patients with stable chronic heart failure, metformin can be administered with regular monitoring of heart and kidney function.
6) Alcohol intake: Alcohol is known to increase the effect of this drug on lactic acid metabolism. Therefore, acute or chronic excessive intake of alcohol should be avoided while taking this medicine.
7) Vitamin B12 level: It is recommended to monitor serum vitamin B12 level annually. The risk of low vitamin B12 levels increases in patients with higher metformin doses, longer treatment duration, and/or with risk factors known to cause vitamin B12 deficiency.
8) Changes in controlled diabetic patients: If abnormal laboratory findings or clinical disease (especially vague and poorly defined disease) occurs in a patient whose type 2 diabetes was previously well controlled with this drug, the patient should be immediately evaluated for the development of ketoacidosis or lactic acidosis. Serum electrolytes, ketones, and blood sugar levels are tested, and, if necessary, blood pH, lactate, pyruvate, and metformin hydrochloride levels are tested. If any form of acidosis appears, immediately stop administering metformin hydrochloride and take other appropriate and correct measures.
9) Hypoglycemia: Hypoglycemia does not occur in patients who take metformin hydrochloride alone under normal use circumstances, but occurs when caloric intake is insufficient, when vigorous exercise is not supplemented by caloric intake, or when other hypoglycemic agents (sulfonylurea, insulin, meglitinide, etc.) or alcohol are administered concurrently. Hypoglycemia is especially likely to occur in the elderly, weak or malnourished patients, patients with adrenal or pituitary insufficiency, or alcoholics. Hypoglycemia may be difficult to identify in older adults and people taking β-adrenergic blocking drugs. If symptoms of hypoglycemia are recognized due to administration of metformin hydrochloride, sugar (sucrose) is generally administered, and if symptoms of hypoglycemia are recognized due to concurrent use with an α-glucosidase inhibitor (acarbose, voglibose), glucose is administered.
10) Failure to control blood sugar: Patients who have been stabilized with certain diabetes treatments may temporarily fail to control blood sugar when exposed to stress such as fever, convulsions, infection, or surgery. At these times, metformin hydrochloride may be discontinued and temporary insulin administration may be required. Metformin hydrochloride can be resumed after the acute crisis has resolved. The effectiveness of oral hypoglycemic agents, which lower blood sugar levels to a certain level, declines after a certain period of time in many patients. This phenomenon, which occurs due to disease progression or decreased response to the drug, is known as secondary failure and is distinct from primary failure, in which the drug is ineffective during the initial treatment period. If there has been secondary failure with metformin hydrochloride and sulfonylurea therapy, it may be necessary to initiate insulin therapy.
11) Patients with specific occupations: In rare cases, severe lactic acidosis and severe delayed hypoglycemia may occur, so caution should be exercised when administering to patients engaged in work at heights or driving a car. In addition, provide sufficient and thorough warning to patients and their families regarding lactic acidosis and hypoglycemia.
12) Patients should be informed of the potential benefits and risks of metformin hydrochloride and other treatment methods. Additionally, they should be informed of the importance of maintaining a diet, regular exercise plan, regular blood sugar testing, glycated hemoglobin, renal function, and hematological values.
The risk of lactic acidosis, its symptoms and possible predispositions should be explained to the patient. If unexplained hyperventilation, muscle pain, fatigue, abnormal confusion, or other unspecified symptoms occur, immediately discontinue metformin hydrochloride and notify the medical staff.
Advise patients about the risks of excessive alcohol consumption, whether acute or chronic, while taking metformin hydrochloride.
Combining metformin hydrochloride with oral sulfonylureas may cause hypoglycemia, but metformin hydrochloride alone usually does not cause acute hypoglycemia. At the beginning of combination therapy, the risk of hypoglycemia, symptoms and treatment, and conditions that may occur should be explained to the patient.
13) It has been reported that the administration of oral hypoglycemic agents is associated with an increase in cardiovascular mortality compared to diet alone or combination treatment of diet and insulin. This warning is based on a study conducted by the University Group Diabetes Program (UGDP) to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with type 2 diabetes. The UGDP reported that the cardiovascular mortality rate in patients who received diet therapy and a prescribed dose of tolbutamide (1.5 g/day) or diet therapy and a prescribed dose of phenpolmine (100 mg/day) for 5 to 8 years was approximately 2.5 times that of patients who only administered diet therapy, resulting in the discontinuation of treatment in both treatment groups. Despite objections to the interpretation of these results, the results of the UGDP study provide a reasonable basis for this warning.
Patients should be informed of the potential benefits and risks of metformin hydrochloride and alternative treatments. Although this study included only one sulfonylurea (tolbutamide) and one biguanide (phenformin), the similarity in mechanism of action and chemical structure among medicines within each class should be considered when applying this warning to other related glucose-lowering medicines.
14) Response to all diabetes treatments should be monitored by regularly measuring fasting blood sugar and glycated hemoglobin levels with the aim of lowering the levels to the normal range. Initially, fasting blood glucose can be used to determine treatment response. Therefore, both blood sugar and glycated hemoglobin should be monitored. Glycosylated hemoglobin levels are particularly useful in assessing long-term control.
15) Initial and regular monitoring of hematological values (e.g. hemoglobin/hematocrit, red blood cell index) and renal function (serum creatinine) should be performed at least once a year. Megaloblastic anemia is rarely observed during treatment with metformin hydrochloride, and if suspected, the possibility of vitamin B12 deficiency should be checked.
16) This medicine should be swallowed whole rather than crushed or chewed. Patients should be informed in advance that this is normal as the tablet shell may pass through the stool.
6. Interaction
1) Since the blood sugar lowering effect may be enhanced or reduced by combined use with the following drugs, when used together, administer while carefully observing the blood sugar level and the condition of other patients.
- Drugs that increase blood sugar lowering action
Insulin preparations, sulfonylamide and sulfonylurea drugs, meglitinides (repaglinide, etc.), β-blockers (propranolol, etc.), MAO inhibitors, alpha-glycosidase inhibitors (alkalophos), anabolic steroids, guanethidine, salicylates (aspirin, etc.)
- Drugs that reduce blood sugar lowering action
Epinephrine, sympathomimetics, corticosteroids, thyroid hormones, follicular hormones, estrogens, oral contraceptives, thiazide and other diuretics, pyrazinamide, isoniazid, nicotinic acid, phenothiazines, phenytoin, calcium channel antagonists.
2) Alcohol: The risk of lactic acidosis increases during the acute alcohol intoxication period, especially in the following circumstances.
- Hungry or malnutrition
- Liver dysfunction
You should avoid drinking alcohol and taking drugs that contain alcohol.
3) Iodine-labeled contrast media: Renal failure may occur in association with intravenous administration of iodine-labeled contrast media, which may cause metformin accumulation and potentially expose patients to the risk of lactic acidosis. Metformin should be discontinued before or at the time of testing with iodine-labeled contrast media, and treatment should be resumed only after at least 48 hours and after reassessment of renal function and determination that there is no risk of further damage. (Refer to 2. Do not administer to the following patients.)
4) Glyburide: In a single-dose study on patients with type 2 diabetes, co-administration of metformin hydrochloride and glyburide did not change the pharmacokinetics or pharmacodynamic properties of metformin hydrochloride. A decrease in the AUC and Cmax of glyburide was observed, but the deviation was large. The lack of correlation between blood concentrations and pharmacokinetic effects of single-dose metformin hydrochloride in this study indicates that the clinical significance of this interaction is unclear.
5) Furosemide: A study on the drug interaction of metformin hydrochloride and furosemide administered as a single dose in healthy people showed that the pharmacokinetic values of each substance were affected by co-administration. Furosemide increases the plasma concentration of metformin hydrochloride without significant changes in the renal clearance of metformin hydrochloride, and increases blood Cmax by 22% and blood AUC by 15%. When administered together with metformin hydrochloride, the Cmax and AUC of furosemide are reduced by 31% and 12%, respectively, compared to single administration, and the terminal half-life of furosemide is reduced by 32% without changing the renal clearance of furosemide. There is no available information regarding the interaction when metformin hydrochloride and furosemide are co-administered chronically.
6) Nifedipine: A study on the drug interaction between metformin hydrochloride and nifedipine in a single dose in normal healthy volunteers showed that co-administration with nifedipine increases the Cmax and AUC of metformin hydrochloride in plasma by 20% and 9%, respectively, and increases urinary excretion. Tmax and half-life are not affected. Nifedipine promotes the absorption of metformin hydrochloride. Metformin hydrochloride does not significantly affect nifedipine.
7) Drugs that may affect metformin hydrochloride, such as cationic drugs that may affect renal function, cause significant hemodynamic changes, or are excreted through renal tubular secretion: Metformin is a substrate of the organic cation transporter (OCT) OCT1 and OCT2.
- When used in combination with OCT1 inhibitors (verapamil, etc.), the efficacy of metformin may be reduced.
- When used in combination with OCT1 inducers (rifampicin, etc.), the gastrointestinal absorption and efficacy of metformin may increase.
- When used in combination with OCT2 inhibitors (cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, etc.), the renal excretion of metformin may be reduced and the blood concentration of metformin may increase.
- When used in combination with OCT2 and OCT1 simultaneous inhibitors (crizotinib, olaparib), the renal excretion and efficacy of metformin may be affected.
Therefore, when metformin and these drugs are administered together, the blood concentration of metformin may increase, so caution is needed, especially in patients with renal impairment. Because OCT inhibitors/inducers may change the efficacy of metformin, dose adjustment of metformin may be considered if necessary.
In addition, nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-II (Cyclo-oxygenase) inhibitors, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor antagonists, and diuretics (especially loop diuretics) may have an adverse effect on renal function and increase the risk of lactic acidosis. Therefore, renal function should be carefully monitored when administered in combination with metformin. Must observe.
8) Others: In a single co-administration study in healthy volunteers, the pharmacokinetic properties of metformin hydrochloride and propranolol, and metformin hydrochloride and ibuprofen were not affected by each other.
Since the binding of metformin hydrochloride to plasma proteins is negligible, there is little interaction with drugs that bind to proteins in large quantities, such as salicylic acid, sulfonamides, chloramphenicol, and probenecid, compared to sulfonylureas, which bind extensively to plasma proteins.
7. Administration to pregnant and lactating women
1) Administration to pregnant women
Uncontrolled hyperglycemia in the periconceptional phase and during pregnancy is associated with an increased risk of congenital abnormalities, miscarriage, pregnancy-induced hypertension, preeclampsia, and perinatal mortality. It is important to keep blood sugar levels as close to normal as possible throughout pregnancy to reduce the risks associated with high blood sugar during pregnancy.
Metformin crosses the placenta, and levels of transplacental passage can be as high as maternal concentrations.
Based on data (>1000 exposures) from various studies (clinical studies, register-based cohort studies, meta-analyses, etc.) on metformin use in the periconceptional phase and during pregnancy, no increased risk of congenital abnormalities and/or fetal/neonatal toxicity due to metformin exposure during the periconceptional phase and/or pregnancy has been identified.
Babies exposed to metformin in utero may be small for gestational age. There is limited evidence on the effects of metformin on long-term birth weight outcomes and metabolic complications in infants. It does not appear to affect motor-social development up to 4 years of age, but results beyond 4 years of age are limited.
If you are planning to become pregnant or are clinically necessary for the purpose of controlling blood sugar levels during pregnancy, the use of metformin may be considered in addition to or as an alternative to insulin.
However, pregnant women at risk for placental insufficiency, preeclampsia, or intrauterine growth retardation should not begin treatment with metformin. Fetal development should be closely monitored to prevent birth weight loss, and metformin administration should be discontinued if fetal growth retardation is confirmed.
2) Administration to nursing mothers
This drug is excreted in breast milk and no adverse reactions have been reported in neonates/infants. However, because reported study results are limited, breastfeeding is not recommended during treatment with this drug. Considering the benefits of breastfeeding, the importance of the drug to the nursing mother, and the potential risk of adverse reactions in the infant, a decision should be made whether to discontinue breastfeeding or drug treatment.
8. Administration to children
Safety and efficacy in children have not been established, so administration to children under 17 years of age is not recommended.
9. Administration to elderly people
Since aging is associated with a decline in renal function in the elderly, the minimum dose that achieves appropriate blood sugar control effects should be set based on the patient's renal function. Elderly patients should regularly monitor their renal function, and the maximum dose of this drug is generally not administered to elderly patients.
10. Treatment in case of overdose
Even if metformin hydrochloride is administered up to 85g, hypoglycemia does not occur even if lactic acidosis occurs in this condition. The drug is dialyzed under good hemodynamic conditions with clearance rates up to 170 mL/min. Therefore, hemodialysis may be useful to remove accumulated drug in patients suspected of overdosing with this drug.
11. Others
1) This drug does not exhibit pharmacokinetic properties that cause primary or secondary regeneration or addiction.
2) Long-term carcinogenicity tests were conducted on rats (dose lasting 104 weeks) and mice (lasting 91 weeks) at doses of 900mg/kg/day and 1500mg/kg/day, respectively. This dose is approximately four times the human body's maximum daily tolerance based on body surface area. There was no evidence of carcinogenicity associated with this drug in either male or female mice. Similarly, there was no tumorigenic potential for this drug in male rats. However, an increase in benign interstitial uterine polyps was observed in female rats administered at 900 mg/kg/day.
There was no evidence of the mutagenic potential of this drug in the reverse mutation test (S.typhimurim), gene mutation test (mouse lymphoma cells), chromosomal aberration test (human lymphocytes), or in vivo micronucleus test (mouse bone marrow cells).
Fertility in male and female rats was not affected by this drug when administered at a high dose of 600 mg/kg/day, or approximately 3 times the maximum tolerated dose based on body surface area.
3) Effect on body weight: Compared to other commonly used hypoglycemic agents (sulfonylureas, chiazolinediones, etc.), this drug is beneficial in the treatment of type 2 diabetes patients as it does not cause weight gain. Maintain or lose weight to limit other risk factors associated with weight gain. Long-term use provides more stable blood sugar control and reduces the risk of diabetes complications. In clinical trials in adults and children, this drug improved glycemic control without or with some weight loss.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle
7. Period of use
36 months from date of manufacture
1 tablet
- Active ingredient: Metformin hydrochloride (BP)----500mg
- Additives: Magnesium stearate, carbomer, hydroxypropyl cellulose, hypromellose 2208
2. Effectiveness
Treatment of adult patients with type 2 diabetes who have insufficient blood sugar control through diet and exercise therapy. (Especially in overweight diabetic patients)
- This drug can be used as monotherapy or in combination with other oral hypoglycemic agents or insulin.
3. Dosage and dosage
The administered dose should be determined for each individual based on drug effectiveness and tolerability, and should not exceed the recommended maximum daily dose.
- The typical initial dose is 500 mg metformin hydrochloride extended-release tablet once a day with dinner.
- The dosage should be adjusted by measuring blood sugar levels after a week. Gastrointestinal adverse reactions can be improved with gradual dose increase. The maximum dose is 2000 mg per day.
- When increasing the dose, increase by 500 mg per week, and up to 2000 mg per day can be administered with dinner. If blood sugar control is not achieved even with up to 2,000 mg once a day, consider administering 1,000 mg twice a day, both times with meals.
- In patients already being treated with metformin tablets, the initial dose of this agent is the same as the daily dose of short-acting metformin tablets. For patients taking more than 2000 mg of short-acting metformin tablets per day, switching to this medication is not recommended.
- When starting medication and adjusting the dose, fasting blood sugar should be measured to measure the therapeutic response to this drug and confirm the minimum effective dose. The concentration of glycated hemoglobin in the blood should be measured at approximately 3-month intervals.
- The treatment goal of this drug is to reduce fasting blood sugar and blood glycated hemoglobin concentration to normal or close to normal levels by administering it at the minimum effective dose when administered as monotherapy or in combination with sulfonylureas or insulin.
patients with renal impairment
This drug can be used in patients with stage 3a moderate renal impairment (creatinine clearance [CrCl] 45≤~<60ml/min or glomerular filtration rate (GFR) 45≤~<60 mL/min/1.73 m2) if they are not accompanied by other symptoms that may increase the risk of lactic acidosis by adjusting the dose as follows.
- The starting dose is 500mg or 750mg once a day. The maximum daily dose is 1000 mg.
Renal function should be closely monitored every 3 to 6 months.
If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, administration of this drug should be discontinued immediately.
4. Precautions for use
1. Warning
1) In rare cases, severe lactic acidosis may occur. Cases of death due to lactic acidosis have been reported.
2) When administered concurrently with other antidiabetic agents such as insulin or sulfonylurea, caution is required as severe hypoglycemia may occur in rare cases.
2. Do not administer to the following patients
1) Patients with moderate (stage3b) and severe renal impairment (creatinine clearance <45ml/min or glomerular filtration rate <45ml/min/1.73m2), acute conditions that may affect renal function such as dehydration, serious infection, cardiovascular collapse (shock), acute myocardial infarction, and sepsis.
2) Patients with acute and unstable heart failure
3) Patients receiving tests that involve intravenous administration of radioiodine contrast material (e.g. intravenous urography, intravenous cholangiography, angiography, computed tomography using contrast media, etc.) (can cause acute renal failure, and are associated with lactic acidosis in patients receiving this drug. Therefore, among patients scheduled for such tests, if the glomerular filtration rate is >60ml/min/1.73m2, at least at the time of the test or in advance The drug must be discontinued, and re-administration is not possible within 48 hours. In patients with moderate renal impairment (glomerular filtration rate 45 to 60 ml/min/1.73 m2), re-administration is not possible within 48 hours after renal function is re-evaluated. Treatment is resumed only after this.)
4) Patients with a history of hypersensitivity to the ingredients of this drug or biguanide drugs
5) Patients with acute or chronic metabolic acidosis, including type 1 diabetes, lactic acidosis, diabetic ketoacidosis with or without coma, and patients with a history of ketoacidosis [Type 1 diabetes and diabetic ketoacidosis are treated with insulin.]
6) Diabetic precoma
7) In patients with severe infections or severe traumatic systemic disorders, treatment with this drug should be temporarily stopped and treatment should be restarted when the patient's oral intake is restored and renal function is found to be normal.
8) In the case of surgical procedures (excluding minor surgeries where there are no restrictions on food and fluid intake), this drug should be temporarily stopped 48 hours before surgery, and treatment should be restarted at least 48 hours after renal function is confirmed to be normal.
9) Patients with malnutrition, starvation, weakness, pituitary dysfunction, or adrenal dysfunction
10) Impaired liver function (since impaired liver function is associated with some cases of lactic acidosis, administration of this drug should generally be avoided in patients with clinical or laboratory evidence of liver disease), acute or chronic diseases that may cause tissue hypoxia such as respiratory failure, acute myocardial infarction, and shock, excessive alcohol intake, and patients with gastrointestinal disorders such as dehydration, diarrhea, and vomiting.
11) Pregnant women at risk of placental insufficiency, preeclampsia, and intrauterine growth retardation (see section 7. Administration for pregnant and lactating women)
3. Administer with caution to the following patients (there is a possibility of lactic acidosis and hypoglycemia).
1) Irregular meal intake, lack of meal intake
2) Intense muscle exercise
3) Patients taking interacting drugs
4. Adverse reactions
In post-marketing surveillance and clinical trial results, the side effects reported in patients receiving this drug were similar in nature and severity to the side effects reported in patients receiving metformin hydrochloride immediate-release tablets.
The following side effects may occur when taking this medicine:
Frequency is defined as follows: Very common: >1/10 Common: >1/100, <1/10 Uncommon: >1/1,000, <1/100 Rare: >1/10,000, <1/1,000 Very rare: <1/10,000
1) Metabolic and nutritional disorders
Common: vitamin B12 deficiency
Very rare: Lactic acidosis (lactic acidosis is rare but serious, and is a metabolic complication caused by accumulation of metformin hydrochloride during treatment. It is fatal in 50% of cases. Lactic acidosis occurs frequently in acute renal dysfunction, cardiopulmonary disease, and sepsis. Lactic acidosis may appear in conjunction with pathophysiological conditions, including diabetes, when there is significant tissue hypoperfusion and hypoxia. Lactic acidosis is characterized by increased blood lactic acid concentration (exceeding 5 mmol/L), decreased blood pH, electrolyte imbalance with increased difference between anions, and increased lactic acid/pyruvate ratio. When metformin hydrochloride is considered to be the cause of lactic acidosis, the blood concentration of metformin hydrochloride generally exceeds 5 μg/mL.
There are very few reports of the development of lactic acidosis in patients receiving metformin hydrochloride (approximately 0.03 cases per 1,000 patients per year, and approximately 0.015 fatal cases per 1,000 patients per year). The reported cases primarily occurred in diabetic patients with significantly reduced renal function, including intrinsic renal disease and renal hypoperfusion, in conditions such as multiple medical and surgical problems and combined administration of many drugs. The risk of lactic acidosis increases with the degree of renal function decline and the patient's age.
In addition, metformin hydrochloride should be discontinued immediately if symptoms related to hypoxia, dehydration, or sepsis appear. If liver function is impaired, the ability to excrete lactic acid may be significantly reduced, so metformin hydrochloride is generally not administered to patients with clinical or laboratory findings of liver disease. Since alcohol has the potential to affect metformin hydrochloride on lactic acid metabolism, acute or chronic excessive intake of alcohol should be avoided while receiving metformin hydrochloride.
The onset of lactic acidosis is sometimes difficult to distinguish and is accompanied by nonspecific symptoms such as malaise, myalgia, dyspnea, asthenia, and abdominal pain. If acidosis becomes more severe, a drop in body temperature, hypotension, and resistant bradyarrhythmia may occur. Patients and doctors should be aware of the importance of these symptoms, and patients should notify their doctors immediately if these symptoms occur. Serum electrolytes, ketones, blood sugar, blood pH (<7.35), lactic acid concentration, and blood metformin hydrochloride concentration may also be useful in confirming lactic acidosis. Additionally, if there is a high suspicion of lactic acidosis, necessary measures are taken without expecting a lactic acid measurement result. In particular, be careful because lactic acidosis is likely to occur when the initial dose is increased. Gastrointestinal symptoms often occur early in treatment once the patient has stabilized on a certain dose of metformin hydrochloride, but later gastrointestinal symptoms may be due to lactic acidosis or another serious illness.
Fasting venous plasma lactate concentrations above the upper limit of normal but below 5 mmol/L in patients receiving metformin hydrochloride do not indicate impending lactic acidosis and may be due to other mechanisms, such as poorly controlled diabetes or obesity, excessive physical activity, or technical problems in specimen handling. Lactic acidosis should be suspected in diabetic patients presenting with metabolic acidosis without evidence of ketoacidosis (ketonuria and ketonemia).
Lactic acidosis is a medical emergency requiring hospitalization. If lactic acidosis occurs in a patient receiving metformin hydrochloride, the drug should be discontinued immediately and general supportive therapy should be immediately administered. Since metformin hydrochloride is dialyzable (clearance up to 170 mL/min in good hemodynamic conditions), immediate hemodialysis is recommended to normalize acidosis and remove accumulated drug. This treatment sometimes results in immediate symptom improvement and recovery.
2) nervous system disorders
Common: taste impairment
3) Gastrointestinal disorders
Very common: Gastrointestinal disorders such as nausea, vomiting, diarrhea, abdominal pain, and anorexia.
These side effects occur most frequently in the early stages of treatment and disappear spontaneously in most cases. Gradually increasing the dose may help increase gastrointestinal tolerability. Since gastrointestinal symptoms occur in a dose-related manner during the initial stage of treatment, they can be reduced by gradually increasing the dose or administering metformin hydrochloride with meals. Severe diarrhea and/or vomiting may cause dehydration and prerenal azotemia and should be temporarily discontinued under these conditions. In patients stabilized on metformin hydrochloride, non-specific gastrointestinal symptoms may not be due to treatment but may be due to concurrent disease or lactic acidosis.
4) Skin and subcutaneous tissue disorders
Very rarely: erythema, itching, urticaria, rash, etc. may occur. In such cases, discontinue administration.
5. General precautions
1) Monitoring of renal function: This drug is mostly excreted by the kidneys, and the risk of accumulation of this drug and lactic acidosis increases depending on the degree of renal function impairment. Glomerular filtration rate should be evaluated before starting treatment and periodically thereafter. Patients with normal renal function should have a renal function test checked at least once a year. Patients with a creatinine clearance lower than normal and the elderly should have a renal function test performed at least 2 to 4 times a year. If the creatinine clearance rate is <45ml/min (glomerular filtration rate <45ml/min/1.73m2), discontinue treatment with this drug.
Special caution is needed in situations that may result in rapid renal function impairment, such as when there are symptoms of dehydration (severe or persistent vomiting or diarrhea) or when starting medications that affect renal function (such as antihypertensive drugs or diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs)). In these acute situations, metformin should be discontinued immediately and temporarily.
2) Diabetes-like symptoms: Consider application only to patients with an established diagnosis of diabetes. Be aware that in addition to diabetes, there are diseases with diabetes-like symptoms such as abnormal glucose tolerance and positive urine glucose (nephrogenic diabetes, geriatric glucose metabolism abnormalities, thyroid dysfunction, etc.).
3) Adjustment during administration: In cases where administration is no longer necessary, when a reduction is necessary, or when the effect becomes ineffective or insufficient due to the patient's deterioration, complications of infection, etc., pay attention to meal intake, weight change, blood sugar level, presence or absence of infection, etc., and pay attention to whether to continue administration, dosage, selection of drug, etc.
4) Hypoxic state: Cardiovascular collapse (shock) of any cause, acute congestive heart failure, acute myocardial infarction and other conditions characterized by hypoxia are associated with lactic acidosis and may cause prerenal azotemia. If this occurs in a patient receiving treatment with this drug, administration of this drug should be discontinued immediately.
5) Cardiac function: Patients with heart failure have a higher risk of hypoxia and decreased renal function. For patients with stable chronic heart failure, metformin can be administered with regular monitoring of heart and kidney function.
6) Alcohol intake: Alcohol is known to increase the effect of this drug on lactic acid metabolism. Therefore, acute or chronic excessive intake of alcohol should be avoided while taking this medicine.
7) Vitamin B12 level: It is recommended to monitor serum vitamin B12 level annually. The risk of low vitamin B12 levels increases in patients with higher metformin doses, longer treatment duration, and/or with risk factors known to cause vitamin B12 deficiency.
8) Changes in controlled diabetic patients: If abnormal laboratory findings or clinical disease (especially vague and poorly defined disease) occurs in a patient whose type 2 diabetes was previously well controlled with this drug, the patient should be immediately evaluated for the development of ketoacidosis or lactic acidosis. Serum electrolytes, ketones, and blood sugar levels are tested, and, if necessary, blood pH, lactate, pyruvate, and metformin hydrochloride levels are tested. If any form of acidosis appears, immediately stop administering metformin hydrochloride and take other appropriate and correct measures.
9) Hypoglycemia: Hypoglycemia does not occur in patients who take metformin hydrochloride alone under normal use circumstances, but occurs when caloric intake is insufficient, when vigorous exercise is not supplemented by caloric intake, or when other hypoglycemic agents (sulfonylurea, insulin, meglitinide, etc.) or alcohol are administered concurrently. Hypoglycemia is especially likely to occur in the elderly, weak or malnourished patients, patients with adrenal or pituitary insufficiency, or alcoholics. Hypoglycemia may be difficult to identify in older adults and people taking β-adrenergic blocking drugs. If symptoms of hypoglycemia are recognized due to administration of metformin hydrochloride, sugar (sucrose) is generally administered, and if symptoms of hypoglycemia are recognized due to concurrent use with an α-glucosidase inhibitor (acarbose, voglibose), glucose is administered.
10) Failure to control blood sugar: Patients who have been stabilized with certain diabetes treatments may temporarily fail to control blood sugar when exposed to stress such as fever, convulsions, infection, or surgery. At these times, metformin hydrochloride may be discontinued and temporary insulin administration may be required. Metformin hydrochloride can be resumed after the acute crisis has resolved. The effectiveness of oral hypoglycemic agents, which lower blood sugar levels to a certain level, declines after a certain period of time in many patients. This phenomenon, which occurs due to disease progression or decreased response to the drug, is known as secondary failure and is distinct from primary failure, in which the drug is ineffective during the initial treatment period. If there has been secondary failure with metformin hydrochloride and sulfonylurea therapy, it may be necessary to initiate insulin therapy.
11) Patients with specific occupations: In rare cases, severe lactic acidosis and severe delayed hypoglycemia may occur, so caution should be exercised when administering to patients engaged in work at heights or driving a car. In addition, provide sufficient and thorough warning to patients and their families regarding lactic acidosis and hypoglycemia.
12) Patients should be informed of the potential benefits and risks of metformin hydrochloride and other treatment methods. Additionally, they should be informed of the importance of maintaining a diet, regular exercise plan, regular blood sugar testing, glycated hemoglobin, renal function, and hematological values.
The risk of lactic acidosis, its symptoms and possible predispositions should be explained to the patient. If unexplained hyperventilation, muscle pain, fatigue, abnormal confusion, or other unspecified symptoms occur, immediately discontinue metformin hydrochloride and notify the medical staff.
Advise patients about the risks of excessive alcohol consumption, whether acute or chronic, while taking metformin hydrochloride.
Combining metformin hydrochloride with oral sulfonylureas may cause hypoglycemia, but metformin hydrochloride alone usually does not cause acute hypoglycemia. At the beginning of combination therapy, the risk of hypoglycemia, symptoms and treatment, and conditions that may occur should be explained to the patient.
13) It has been reported that the administration of oral hypoglycemic agents is associated with an increase in cardiovascular mortality compared to diet alone or combination treatment of diet and insulin. This warning is based on a study conducted by the University Group Diabetes Program (UGDP) to evaluate the effectiveness of glucose-lowering drugs in preventing or delaying vascular complications in patients with type 2 diabetes. The UGDP reported that the cardiovascular mortality rate in patients who received diet therapy and a prescribed dose of tolbutamide (1.5 g/day) or diet therapy and a prescribed dose of phenpolmine (100 mg/day) for 5 to 8 years was approximately 2.5 times that of patients who only administered diet therapy, resulting in the discontinuation of treatment in both treatment groups. Despite objections to the interpretation of these results, the results of the UGDP study provide a reasonable basis for this warning.
Patients should be informed of the potential benefits and risks of metformin hydrochloride and alternative treatments. Although this study included only one sulfonylurea (tolbutamide) and one biguanide (phenformin), the similarity in mechanism of action and chemical structure among medicines within each class should be considered when applying this warning to other related glucose-lowering medicines.
14) Response to all diabetes treatments should be monitored by regularly measuring fasting blood sugar and glycated hemoglobin levels with the aim of lowering the levels to the normal range. Initially, fasting blood glucose can be used to determine treatment response. Therefore, both blood sugar and glycated hemoglobin should be monitored. Glycosylated hemoglobin levels are particularly useful in assessing long-term control.
15) Initial and regular monitoring of hematological values (e.g. hemoglobin/hematocrit, red blood cell index) and renal function (serum creatinine) should be performed at least once a year. Megaloblastic anemia is rarely observed during treatment with metformin hydrochloride, and if suspected, the possibility of vitamin B12 deficiency should be checked.
16) This medicine should be swallowed whole rather than crushed or chewed. Patients should be informed in advance that this is normal as the tablet shell may pass through the stool.
6. Interaction
1) Since the blood sugar lowering effect may be enhanced or reduced by combined use with the following drugs, when used together, administer while carefully observing the blood sugar level and the condition of other patients.
- Drugs that increase blood sugar lowering action
Insulin preparations, sulfonylamide and sulfonylurea drugs, meglitinides (repaglinide, etc.), β-blockers (propranolol, etc.), MAO inhibitors, alpha-glycosidase inhibitors (alkalophos), anabolic steroids, guanethidine, salicylates (aspirin, etc.)
- Drugs that reduce blood sugar lowering action
Epinephrine, sympathomimetics, corticosteroids, thyroid hormones, follicular hormones, estrogens, oral contraceptives, thiazide and other diuretics, pyrazinamide, isoniazid, nicotinic acid, phenothiazines, phenytoin, calcium channel antagonists.
2) Alcohol: The risk of lactic acidosis increases during the acute alcohol intoxication period, especially in the following circumstances.
- Hungry or malnutrition
- Liver dysfunction
You should avoid drinking alcohol and taking drugs that contain alcohol.
3) Iodine-labeled contrast media: Renal failure may occur in association with intravenous administration of iodine-labeled contrast media, which may cause metformin accumulation and potentially expose patients to the risk of lactic acidosis. Metformin should be discontinued before or at the time of testing with iodine-labeled contrast media, and treatment should be resumed only after at least 48 hours and after reassessment of renal function and determination that there is no risk of further damage. (Refer to 2. Do not administer to the following patients.)
4) Glyburide: In a single-dose study on patients with type 2 diabetes, co-administration of metformin hydrochloride and glyburide did not change the pharmacokinetics or pharmacodynamic properties of metformin hydrochloride. A decrease in the AUC and Cmax of glyburide was observed, but the deviation was large. The lack of correlation between blood concentrations and pharmacokinetic effects of single-dose metformin hydrochloride in this study indicates that the clinical significance of this interaction is unclear.
5) Furosemide: A study on the drug interaction of metformin hydrochloride and furosemide administered as a single dose in healthy people showed that the pharmacokinetic values of each substance were affected by co-administration. Furosemide increases the plasma concentration of metformin hydrochloride without significant changes in the renal clearance of metformin hydrochloride, and increases blood Cmax by 22% and blood AUC by 15%. When administered together with metformin hydrochloride, the Cmax and AUC of furosemide are reduced by 31% and 12%, respectively, compared to single administration, and the terminal half-life of furosemide is reduced by 32% without changing the renal clearance of furosemide. There is no available information regarding the interaction when metformin hydrochloride and furosemide are co-administered chronically.
6) Nifedipine: A study on the drug interaction between metformin hydrochloride and nifedipine in a single dose in normal healthy volunteers showed that co-administration with nifedipine increases the Cmax and AUC of metformin hydrochloride in plasma by 20% and 9%, respectively, and increases urinary excretion. Tmax and half-life are not affected. Nifedipine promotes the absorption of metformin hydrochloride. Metformin hydrochloride does not significantly affect nifedipine.
7) Drugs that may affect metformin hydrochloride, such as cationic drugs that may affect renal function, cause significant hemodynamic changes, or are excreted through renal tubular secretion: Metformin is a substrate of the organic cation transporter (OCT) OCT1 and OCT2.
- When used in combination with OCT1 inhibitors (verapamil, etc.), the efficacy of metformin may be reduced.
- When used in combination with OCT1 inducers (rifampicin, etc.), the gastrointestinal absorption and efficacy of metformin may increase.
- When used in combination with OCT2 inhibitors (cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole, etc.), the renal excretion of metformin may be reduced and the blood concentration of metformin may increase.
- When used in combination with OCT2 and OCT1 simultaneous inhibitors (crizotinib, olaparib), the renal excretion and efficacy of metformin may be affected.
Therefore, when metformin and these drugs are administered together, the blood concentration of metformin may increase, so caution is needed, especially in patients with renal impairment. Because OCT inhibitors/inducers may change the efficacy of metformin, dose adjustment of metformin may be considered if necessary.
In addition, nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-II (Cyclo-oxygenase) inhibitors, angiotensin-converting enzyme inhibitors (ACE inhibitors), angiotensin II receptor antagonists, and diuretics (especially loop diuretics) may have an adverse effect on renal function and increase the risk of lactic acidosis. Therefore, renal function should be carefully monitored when administered in combination with metformin. Must observe.
8) Others: In a single co-administration study in healthy volunteers, the pharmacokinetic properties of metformin hydrochloride and propranolol, and metformin hydrochloride and ibuprofen were not affected by each other.
Since the binding of metformin hydrochloride to plasma proteins is negligible, there is little interaction with drugs that bind to proteins in large quantities, such as salicylic acid, sulfonamides, chloramphenicol, and probenecid, compared to sulfonylureas, which bind extensively to plasma proteins.
7. Administration to pregnant and lactating women
1) Administration to pregnant women
Uncontrolled hyperglycemia in the periconceptional phase and during pregnancy is associated with an increased risk of congenital abnormalities, miscarriage, pregnancy-induced hypertension, preeclampsia, and perinatal mortality. It is important to keep blood sugar levels as close to normal as possible throughout pregnancy to reduce the risks associated with high blood sugar during pregnancy.
Metformin crosses the placenta, and levels of transplacental passage can be as high as maternal concentrations.
Based on data (>1000 exposures) from various studies (clinical studies, register-based cohort studies, meta-analyses, etc.) on metformin use in the periconceptional phase and during pregnancy, no increased risk of congenital abnormalities and/or fetal/neonatal toxicity due to metformin exposure during the periconceptional phase and/or pregnancy has been identified.
Babies exposed to metformin in utero may be small for gestational age. There is limited evidence on the effects of metformin on long-term birth weight outcomes and metabolic complications in infants. It does not appear to affect motor-social development up to 4 years of age, but results beyond 4 years of age are limited.
If you are planning to become pregnant or are clinically necessary for the purpose of controlling blood sugar levels during pregnancy, the use of metformin may be considered in addition to or as an alternative to insulin.
However, pregnant women at risk for placental insufficiency, preeclampsia, or intrauterine growth retardation should not begin treatment with metformin. Fetal development should be closely monitored to prevent birth weight loss, and metformin administration should be discontinued if fetal growth retardation is confirmed.
2) Administration to nursing mothers
This drug is excreted in breast milk and no adverse reactions have been reported in neonates/infants. However, because reported study results are limited, breastfeeding is not recommended during treatment with this drug. Considering the benefits of breastfeeding, the importance of the drug to the nursing mother, and the potential risk of adverse reactions in the infant, a decision should be made whether to discontinue breastfeeding or drug treatment.
8. Administration to children
Safety and efficacy in children have not been established, so administration to children under 17 years of age is not recommended.
9. Administration to elderly people
Since aging is associated with a decline in renal function in the elderly, the minimum dose that achieves appropriate blood sugar control effects should be set based on the patient's renal function. Elderly patients should regularly monitor their renal function, and the maximum dose of this drug is generally not administered to elderly patients.
10. Treatment in case of overdose
Even if metformin hydrochloride is administered up to 85g, hypoglycemia does not occur even if lactic acidosis occurs in this condition. The drug is dialyzed under good hemodynamic conditions with clearance rates up to 170 mL/min. Therefore, hemodialysis may be useful to remove accumulated drug in patients suspected of overdosing with this drug.
11. Others
1) This drug does not exhibit pharmacokinetic properties that cause primary or secondary regeneration or addiction.
2) Long-term carcinogenicity tests were conducted on rats (dose lasting 104 weeks) and mice (lasting 91 weeks) at doses of 900mg/kg/day and 1500mg/kg/day, respectively. This dose is approximately four times the human body's maximum daily tolerance based on body surface area. There was no evidence of carcinogenicity associated with this drug in either male or female mice. Similarly, there was no tumorigenic potential for this drug in male rats. However, an increase in benign interstitial uterine polyps was observed in female rats administered at 900 mg/kg/day.
There was no evidence of the mutagenic potential of this drug in the reverse mutation test (S.typhimurim), gene mutation test (mouse lymphoma cells), chromosomal aberration test (human lymphocytes), or in vivo micronucleus test (mouse bone marrow cells).
Fertility in male and female rats was not affected by this drug when administered at a high dose of 600 mg/kg/day, or approximately 3 times the maximum tolerated dose based on body surface area.
3) Effect on body weight: Compared to other commonly used hypoglycemic agents (sulfonylureas, chiazolinediones, etc.), this drug is beneficial in the treatment of type 2 diabetes patients as it does not cause weight gain. Maintain or lose weight to limit other risk factors associated with weight gain. Long-term use provides more stable blood sugar control and reduces the risk of diabetes complications. In clinical trials in adults and children, this drug improved glycemic control without or with some weight loss.
12. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle, 300 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 5items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 5 | Daimit XR Tab. | Precautions for use | 2026.10.02 | PDF0045_200702272_Precautions for use (Dimit XR tablet).pdf |
| 4 | Daimit XR Tab. | Precautions for use | 2023.07.21 | PDFPrecautions for use of DimitX R extended-release tablet (draft).pdf |
| 3 | Daimit XR Tab. | Dymit XR extended-release tablet (precautions for use) | 2018.07.09 | PDFDymit XR Extended Release Tablet.pdf |
| 2 | Daimit XR Tab. | DimitX R extended-release tablets (dosage, instructions for use... | 2018.01.03 | PDFMetformin hydrochloride single tablet_Western tablet unification adjustment plan.pdf |
| 1 | Daimit XR Tab. | Dymit XR extended-release tablets (efficacy, dosage, usage... | 2014.01.14 | HWPUnification adjustment for metformin hydrochloride single agent (oral-sustained release tablet) (draft). |